Heart Closure Devices Market – By Product, By Material, By Mode of Delivery, By End Use – Global Forecast, 2025 to 2034

Heart Closure Devices Market Size

The global heart closure devices market was valued at USD 4 billion in 2024 and is expected to exhibit growth at a CAGR of 15.9% from 2025 to 2034. High market growth can be attributed to the growing prevalence of cardiovascular diseases, rising preference for minimally invasive procedures, and favorable reimbursement policies, among other contributing factors.

Cardiovascular diseases (CVDs) continue to be a primary global health concern, claiming millions of lives annually. According to the World Health Organization (WHO), CVDs account for approximately 17.9 million deaths each year. Contributing to this alarming trend are an aging population, a surge in lifestyle-related risk factors such as obesity, hypertension, and diabetes, and increasingly sedentary lifestyles. As a result, there is a heightened demand for minimally invasive solutions, such as heart closure devices, which effectively address structural heart defects across diverse patient demographics.
 

Additionally, heart closure devices are highly sought after due to their minimally invasive nature, offering patients an alternative to traditional open-heart surgery. These devices are typically implanted via catheter-based procedures, leading to shorter recovery times, less pain, and reduced hospital stays compared to surgical interventions. As minimally invasive procedures gain popularity among both healthcare providers and patients, the demand for heart closure devices continues to expand, supporting significant growth in the market.
 

Heart closure devices are medical devices used to close abnormal openings in the heart, particularly atrial or ventricular septal defects. These defects are congenital conditions where abnormal openings exist between the chambers of the heart, allowing blood to flow in unintended directions.
 

Heart Closure Devices Market Trends

Technological advancements are significantly propelling growth in the market, enabling the development of safer, more effective, and minimally invasive solutions for patients with structural heart conditions.
 

• Innovations in biomaterials have led to heart closure devices that are more biocompatible, reducing the risk of adverse reactions and enhancing patient outcomes. Modern devices now utilize materials that minimize blood clot formation and device-related infections. For instance, bioresorbable materials dissolve naturally over time, which is particularly beneficial in pediatric cases where long-term device implantation may not be ideal. These advancements have enhanced the safety profile of heart closure devices, increasing both patient and clinician confidence in their use.
   
• Additionally, improvements in imaging technologies, including 3D echocardiography and intracardiac ultrasound, have transformed the precision with which heart defects can be visualized and treated. These advanced imaging systems provide real-time, high-resolution visuals of the heart's structure, allowing for accurate placement of closure devices and reducing procedural risks. The ability to more accurately locate and treat defects leads to better patient outcomes, driving further adoption of heart closure devices as the standard of care for structural heart abnormalities.
   

Heart Closure Devices Market Analysis

Based on product, the market is classified into left atrial appendage (LAA) closure devices, atrial septal defect (ASD) closure devices, ventricular septal defect (VSD) closure devices, patent foramen ovale (PFO) closure devices, and other products. The left atrial appendage (LAA) closure devices segment generated the highest revenue of USD 2.2 billion in 2024.
 

• The dominant market share of left atrial appendage closure (LAAC) devices in heart closure treatment is attributed to their numerous benefits. The primary advantage of these devices is the significant reduction in stroke risk. LAAC devices offer an alternative to long-term anticoagulant therapy, such as warfarin or direct oral anticoagulants (DOACs), which are often linked to potential bleeding complications, drug interactions, and the need for regular monitoring. This is especially beneficial for patients at high risk of bleeding due to factors like advanced age, a history of gastrointestinal bleeding, or the use of other medications.
   
• Additionally, the growing preference for minimally invasive procedures has further propelled the market share of LAAC devices. These devices are increasingly favored over traditional surgical methods due to their lower complication rates, shorter hospital stays, and quicker recovery times. As a result, the adoption of LAAC devices is expected to continue rising, driven by advancements in technology and increasing awareness among healthcare providers and patients about their benefits.
   

Based on material, the heart closure devices market is classified into nitinol-based devices, stainless steel devices, and other materials. The nitinol-based devices segment is expected to drive business growth and expand at a CAGR of 16%, reaching over USD 9.2 billion by 2034.
 

• The dominant market share of nitinol-based heart closure devices is due to their superelasticity and excellent biocompatibility. Nitinol enables these devices to be compressed into a delivery catheter for minimally invasive procedures. Its superelasticity allows the device to endure the dynamic forces and movements within the heart while maintaining its shape and function.
   
• Additionally, the increasing prevalence of cardiovascular diseases has driven the demand for effective heart closure solutions. Nitinol-based devices are particularly advantageous due to their durability and adaptability, which ensure long-term performance and patient safety. As healthcare providers seek reliable and efficient treatment options, the market share of nitinol-based heart closure devices is expected to grow, supported by ongoing innovations.
   

Based on mode of delivery, the heart closure devices market is classified into transcatheter delivery and surgical delivery. The transcatheter delivery segment generated the highest revenue of USD 2.5 billion in 2024.
 

• Transcatheter delivery offers a less invasive alternative to open-heart surgery by making small incisions or punctures in the skin instead of a large chest incision. This method results in smaller scars, less pain, a reduced risk of infection, and shorter recovery times. Patients undergoing transcatheter closure procedures typically experience quicker recovery periods compared to those who have open-heart surgery. Additionally, transcatheter procedures are associated with lower risks of complications such as infection, bleeding, and other surgical issues.
   
• Moreover, the growing preference for transcatheter delivery in heart closure devices is driven by its numerous benefits. The reduced invasiveness and associated lower complication rates make it an attractive option for both patients and healthcare providers. As advancements in transcatheter technology continue, and awareness of its advantages spreads, the market share of transcatheter heart closure devices is expected to expand significantly.
   

Based on end use, the heart closure devices market is segmented into hospitals, ambulatory surgical centers (ASCs), cardiac catheterization laboratories, and other end users. The hospitals segment dominated the market in 2024 and is anticipated to reach USD 8.6 billion by the end of the forecast period.
 

• Hospitals have the advanced facilities, equipment, and specialized medical expertise required for complex heart closure interventions, including treatments for atrial septal defects, patent foramen ovale, and ventricular septal defects. Given the critical nature of these procedures, patients often prefer the comprehensive resources available at hospitals, where they can benefit from the immediate support of multidisciplinary medical teams.
   
• Additionally, heart closure procedures require the expertise of skilled cardiologists, interventional radiologists, and specialized nursing staff. Hospitals attract highly trained professionals who can manage complex procedures and ensure patient safety throughout treatment. The availability of trained personnel ensures high standards of care and successful outcomes for patients undergoing heart closure interventions, reinforcing the hospital segment’s stronghold in this market.
   

North America heart closure devices market accounted for USD 2.7 billion in market revenue in 2024 and is anticipated to grow at a CAGR of 14.3% between the 2025 and 2034.
 

• The region has seen a steady rise in conditions like atrial septal defect (ASD) and patent foramen ovale (PFO), which often require heart closure interventions. Additionally, North America benefits from the early adoption of advanced technologies, such as minimally invasive catheter-based procedures, and substantial investments in research and development, fostering innovations in heart closure devices.
   
• Favorable reimbursement policies also enhance the accessibility of these procedures, further boosting market growth. The presence of key industry players in the U.S. and Canada further supports North America’s market dominance by facilitating widespread product availability and regular technological advancements.
   

France heart closure devices market is projected to grow remarkably in the coming years.
 

• The French healthcare system places a strong emphasis on early detection and treatment of cardiovascular diseases, including congenital heart conditions that often necessitate heart closure devices. France also has numerous specialized cardiac care centers and skilled cardiologists, making it a hub for advanced cardiac treatments.
   
• Moreover, government health initiatives and insurance policies encourage patients to seek treatments for structural heart issues, including ASD and PFO. As a result, demand for heart closure devices in France is growing, with a robust infrastructure supporting the adoption of innovative, minimally invasive heart closure solutions.
   

Japan holds a dominant position in the Asia Pacific heart closure devices market.
 

• The country’s focus on technological innovation has accelerated the adoption of cutting-edge heart closure devices, including bioresorbable and high-precision devices.
   
• Additionally, the government’s initiatives to improve heart health and increase access to cardiovascular devices have further contributed to Japan’s strong position in this market.
   

Heart Closure Devices Market Share

The market is highly competitive, with key players including large multinationals like Abbott Laboratories, Boston Scientific Corporation, and Medtronic plc, which lead in innovation and extensive product portfolios. Regional companies and new entrants, particularly from APAC, are intensifying competition with affordable heart closure devices tailored for local markets. The market sees frequent technological advancements, such as advanced design, enhanced comfort, and precision and data tracking systems, which drive ongoing product development.
 

Heart Closure Devices Market Companies

Prominent players operating in the heart closure devices industry include:

• Abbott Laboratories
• AtriCure
• Biosense Webster
• Boston Scientific Corporation
• Cardia
• Heartstitch
• Lepu Medical Technology (Beijing)Co., Ltd.
• LifeTech Scientific Corporation
• Medtronic
• Occlutech
• SentreHEART
• Starway Medical Technology
• W. L. Gore & Associates
   

Heart Closure Devices Industry News:

• In September 2022, Abbott announced the European launch of Amplatzer Talisman System to close the hole in the heart for people at risk of recurrent stroke. Abbott's Talisman system seals an opening in the heart known as a patent foramen ovale (PFO) to prevent blood clots from passing from the right to the left side of the heart and onto the brain, where they can cause a stroke. Thus, this product launch assisted the company in strengthening its market presence in Europe.
   

The heart closure devices market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million and volume in Units from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Atrial septal defect (ASD) closure devices
• Ventricular septal defect (VSD) closure devices
• Patent foramen ovale (PFO) closure devices
• Left atrial appendage (LAA) closure devices
• Other products

Market, By Material

• Nitinol-based devices
• Stainless steel devices
• Other materials

Market, By Mode of Delivery

• Transcatheter delivery
• Surgical delivery

Market, By End Use

• Hospitals
• Ambulatory surgical centers (ASCs)
• Cardiac catheterization laboratories
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE